GreenLight Biosciences Holdings, PBC (GRNA)
| Market Cap | 887.03M |
| Revenue (ttm) | 1.85M |
| Net Income (ttm) | -169.01M |
| Shares Out | 123.20M |
| EPS (ttm) | -18.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,930 |
| Open | 7.39 |
| Previous Close | 7.38 |
| Day's Range | 7.14 - 7.47 |
| 52-Week Range | 4.83 - 15.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GRNA
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Financial Performance
In 2021, GRNA's revenue was $1.60 million, a decrease of -8.70% compared to the previous year's $1.75 million. Losses were -$112.31 million, 110.9% more than in 2020.
Financial StatementsNews
GreenLight's honeybee-saving RNA solution named finalist in World Changing Ideas Award
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 W...
Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant healt...
GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India...
BOSTON and PUNE, India, March 14, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating acces...
Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nas...
BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination wit...
GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatm...
BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could ...
ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Req...
BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation ("ENVI" or the "Company") (Nasdaq: ENVI) today announced that it had achieved a quorum for the special meeting of its s...
ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 S...
BOSTON, Jan. 14, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive ...
GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and it...
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manuf...
BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessibl...
Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisit...
BOSTON, Nov. 23, 2021 /PRNewswire/ -- GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) today announced an expansion of its PI...
Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board
BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific ...
GreenLight Biosciences opens RNA production facility for the next generation of agricultural products
ROCHESTER, N.Y., Sept. 22, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced th...
RNA Tech Vaccine Developer GreenLight Biosciences Riding To NASDAQ Debut Via $1.5B SPAC Deal
GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion. GreenLight is merging with Environmen...
Vaccine developer GreenLight is going public in a $1.5 billion SPAC deal
As some high-profile SPACs have imploded or fallen afoul of regulators, investors have increasingly shied away from the space.
GreenLight Biosciences Announces Business Agreement With Environmental Impact Acquisition Corp. to Become Publicly Tr...
BOSTON--(BUSINESS WIRE)--GreenLight Biosciences announces business agreement with Environmental Impact Acquisition Corp. to become publicly traded company